# Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

> **NCT06446726** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 30 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab
- **RADIATION:** Low-dose radiotherapy
- **DRUG:** Nab-paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06446726
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-30
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446726, "Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06446726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*